Full-Life Technologies, a Brussels, Belgium- and Shanghai, China-based radiotherapeutics company, acquired Focus-X Therapeutics, a NJ-based company developing targeted radiopharmaceuticals to treat cancer based on proprietary peptide engineering technology.
Under the terms of the acquisition, Focus-X shareholders are eligible to receive from Full-Life an upfront payment, potential development, regulatory and sales-based milestones of up to $245 million and royalties on any commercial sales. The acquisition is expected to close in the first quarter of 2023.
With the acquisition, Full-Life Technologies will accelerate its transformation into a clinical stage radiopharmaceutical company, leveraging its European-focused radiotechnology and development platform.
Led by CEO Fa Liu, Focus-X Therapeutics has developed a proprietary engineering platform to develop peptide radioligands that precisely deliver alpha or beta emitters to breakdown cancer cell DNA. The platform enables optimization of peptide radioligand vectors for key pharmaceutical attributes such as biodistribution, binding affinity and in vivostability.
Led by CEO Lanny Sun, Full-Life Technologies is an integrated radiopharmaceutical company with operations in Europe and China. The company seeks to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments.
FinSMEs
29/11/2022